HANALL BIOPHARMA

Dear customers and shareholders,
Welcome to our website. I am Seung-kook Park, CEO of HanAll Biopharma. Founded in 1973 with the great goal of promoting human health, HanAll Biopharma has developed into an innovative pharmaceutical company with a vision of “the world’s best biotech company to research and develop innovative new drugs and a respected pharmaceutical company that contributes to the health of patients worldwide.”

As Daewoong Pharmaceutical has joined the management of the company with equity investment since 2015, HanAll Biopharma has become able to devote itself to research and development of global innovative new drugs in a more stable environment.

HanAll Biopharma is committed to researching first-in-class and best-in-class biopharmaceuticals that can be a source of hope for patients with rare and incurable diseases who are suffering from no proper treatment.

HanAll Biopharma is researching and developing new antibody drugs with mechanism of action, which is capable of treating various rare autoimmune diseases that occur due to autoantibodies; an anti-TNF bio pharmaceutical, which is developed for the first time for inflammatory eye diseases such as dry eye disease, uveitis, and macular degeneration; and a new immuno-oncology antibody drug with a novel target that strengthens immune response and cure a cancer. The new drugs are already in phase 2 and phase 3 of the global clinical trials. We have already signed three global out-licensing agreements in recognition of innovative and potential value of HanAll Biopharma at the global technology trading market.

The motto of HanAll Biopharma’s R&D is "Think without a limit and act without a boundary".

There are no limits to first-in-class drug ideas to give hope to patients with rare incurable diseases, and there are no boundaries in realizing these ideas for the best solution. We will cooperate with competent companies regardless of their nationality. New antibody drugs for autoimmune diseases and an anti-TNF biopharmaceutical for dry eye disease, developed in cooperation with Roivant Sciences of the U.S., Harbour BioMed of China and Daewoong Pharmaceutical of Korea, are the results of these efforts. In the future, HanAll Biopharma will continue to strive to become a respected biotechnology company that contributes to the health of patients around the world by developing innovative new drugs with competence and enthusiasm.

In the future, HanAll Biopharma will repay customers and shareholders for your trust with development of global innovative new drugs, and ethical management and sales. I look forward to your continued interest and encouragement. Thank you.

CEO of HanAll Biopharma,